ImmuCell Corporation (ICCC)
NASDAQ: ICCC · Real-Time Price · USD
10.75
+0.53 (5.19%)
Nov 13, 2026, 4:00 PM EST - Market closed
ImmuCell Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 33.21 | 27.64 | 26.49 | 17.47 | 18.57 | 19.24 | |
Revenue Growth | 19.59% | 4.35% | 51.63% | -5.90% | -3.51% | 25.42% |
Cost of Revenue | 19.65 | 16.2 | 18.55 | 13.08 | 10.33 | 10.59 |
Gross Profit | 13.56 | 11.45 | 7.94 | 4.4 | 8.24 | 8.66 |
Selling, General & Admin | 8.58 | 5.95 | 5.68 | 5.22 | 5.45 | 4.23 |
Research & Development | 1.37 | 3.04 | 3.9 | 4.39 | 4.49 | 4.17 |
Operating Expenses | 7.96 | 9 | 9.58 | 9.62 | 9.95 | 8.4 |
Operating Income | 5.6 | 2.45 | -1.64 | -5.22 | -1.71 | 0.26 |
Interest Expense | -0.49 | -0.49 | -0.57 | -0.48 | -0.35 | -0.31 |
Interest & Investment Income | 0.16 | 0.16 | 0.08 | 0.1 | 0.15 | 0.02 |
Other Non Operating Income (Expenses) | -0.2 | 0 | - | 0 | 0 | - |
EBT Excluding Unusual Items | 5.07 | 2.12 | -2.13 | -5.6 | -1.9 | -0.04 |
Merger & Restructuring Charges | -0.8 | -0.8 | - | - | - | - |
Gain (Loss) on Sale of Assets | -0.11 | -0.11 | -0.02 | -0.01 | 0.01 | -0.03 |
Asset Writedown | -2.67 | -2.67 | - | - | - | - |
Other Unusual Items | - | - | - | -0.53 | -0.59 | - |
Pretax Income | 1.92 | -1.03 | -2.15 | -5.77 | -2.49 | -0.07 |
Income Tax Expense | 0.04 | 0.01 | 0.01 | 0 | 0.01 | 0.01 |
Net Income | 1.88 | -1.04 | -2.16 | -5.77 | -2.49 | -0.08 |
Net Income to Common | 1.88 | -1.04 | -2.16 | -5.77 | -2.49 | -0.08 |
Net Income Growth | -19.11% | - | - | - | - | - |
Shares Outstanding (Basic) | 9 | 9 | 8 | 8 | 8 | 8 |
Shares Outstanding (Diluted) | 9 | 9 | 8 | 8 | 8 | 8 |
Shares Change | 1.70% | 10.52% | 5.42% | 0.03% | 2.01% | 5.25% |
EPS (Basic) | 0.21 | -0.12 | -0.26 | -0.75 | -0.32 | -0.01 |
EPS (Diluted) | 0.20 | -0.12 | -0.26 | -0.75 | -0.32 | -0.01 |
EPS Growth | -23.86% | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 5.4 | 1.22 | -0.11 | -6.57 | -5.52 | -1.65 |
Free Cash Flow Per Share | 0.59 | 0.14 | -0.01 | -0.85 | -0.71 | -0.22 |
Gross Margin | 40.83% | 41.40% | 29.97% | 25.16% | 44.37% | 44.98% |
Operating Margin | 16.88% | 8.86% | -6.19% | -29.88% | -9.21% | 1.34% |
Profit Margin | 5.66% | -3.76% | -8.14% | -33.05% | -13.43% | -0.41% |
Free Cash Flow Margin | 16.27% | 4.43% | -0.41% | -37.59% | -29.72% | -8.60% |
EBITDA | 7.77 | 5.18 | 1.05 | -2.5 | 0.78 | 2.72 |
EBITDA Margin | 23.39% | 18.73% | 3.95% | -14.33% | 4.19% | 14.13% |
D&A For EBITDA | 2.16 | 2.73 | 2.69 | 2.72 | 2.49 | 2.46 |
EBIT | 5.6 | 2.45 | -1.64 | -5.22 | -1.71 | 0.26 |
EBIT Margin | 16.88% | 8.86% | -6.19% | -29.88% | -9.21% | 1.34% |
Effective Tax Rate | 2.31% | - | - | - | - | - |